Ultrasound-assisted extraction of walnut protein uncovered three small peptides (YIQ, IYQ, IKQ) that inhibit the blood pressure enzyme ACE through an anti-competitive mechanism and are non-toxic to human cells.
21.7% estimated in vivo utilizationComputational prediction for the novel IKQ peptide — suggesting roughly one-fifth could theoretically reach its target after oral intake
What the researchers found
Three ACE-inhibiting peptides from walnut protein — including the novel designed peptide IKQ — block ACE through anti-competitive inhibition and promote nitric oxide production in human endothelial cells without toxicity.
Why it matters
Finding natural ACE inhibitors in everyday foods like walnuts opens the door to functional food products that support blood pressure management — especially noteworthy because these peptides use an unusual inhibition mechanism that could complement existing drugs.
The numbers in context
Optimal ultrasonic pretreatment: 15 minutes at 400 watts. Multiple ACE-inhibiting peptide sequences identified and validated by in silico and in vitro methods.
How the study worked
Walnut protein isolate was extracted with optimized ultrasound (400 W, 15 min), hydrolyzed enzymatically, and fractionated via ultrafiltration, ion exchange chromatography, and LC-MS/MS. Peptides were screened in silico (ADMET, molecular docking) and validated with in vitro ACE inhibition assays and HUVEC cell viability/NO assays.
Who was studied
In vitro enzyme assay and computational modeling
What this study cannot tell us
Entirely in vitro and computational — no evidence these peptides survive human digestion, reach the bloodstream, or lower blood pressure in a living organism. The 21.7% utilization rate is a computational estimate, not measured in vivo. Anti-competitive inhibition is interesting but its practical advantage over competitive inhibition is unproven.
How to read the evidence
Preliminary evidence from in vitro enzyme assays and computational modeling. No animal or human studies have been conducted with these specific peptides.
When this study was published
Published in 2024, representing current food science research on bioactive peptides from plant proteins.
The bigger picture
ACE inhibitors are among the most prescribed drugs for hypertension. Finding food-derived alternatives with novel mechanisms (anti-competitive rather than competitive inhibition) adds to a growing library of bioactive peptides that could be incorporated into functional foods or nutraceuticals for people who prefer dietary approaches to blood pressure management.
Questions still open
- Do these walnut peptides survive gastric digestion and intestinal absorption intact?
- Could the anti-competitive mechanism offer advantages over conventional competitive ACE inhibitors in clinical use?
- What dose of walnuts or walnut protein would be needed to achieve meaningful ACE inhibition in humans?
Common questions
Can eating walnuts actually lower blood pressure through these peptides?
What makes anti-competitive ACE inhibition different from regular ACE inhibitors?
Read the original research
Screening and Constructing of Novel Angiotensin I-Converting Enzyme Inhibiting Peptides from Walnut Protein Isolate and Their Mechanisms of Action: A Merged In Silico and In Vitro Study.
Plant foods for human nutrition (Dordrecht, Netherlands), 79(1), 48-58
Citation
Wang, Yuzhen; Tang, Hengkuan; Deng, Xinyue; Shen, Yijie; Tang, Mingjian; Wang, Fengjun. (2024). Screening and Constructing of Novel Angiotensin I-Converting Enzyme Inhibiting Peptides from Walnut Protein Isolate and Their Mechanisms of Action: A Merged In Silico and In Vitro Study.. Plant foods for human nutrition (Dordrecht, Netherlands), 79(1), 48-58. https://doi.org/10.1007/s11130-023-01122-1